EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes

Ingo V Hartung iD, Joachim Rudolph iD, Mary M Mader iD, Monique P C Mulder iD, Paul Workman iD

Journal of Medicinal Chemistry · 27.07.2023 · 66 (14) · 9297-9312

DOI: 10.1021/acs.jmedchem.3c00550 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 05.07.2023. Verfasst von Ingo V Hartung und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Chemistry, Global Research & Development, Merck Healthcare KGaA, 64293 Darmstadt, Germany. Hauptthemen laut MEDLINE: Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 107-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Within druggable target space, new small-molecule modalities, particularly covalent inhibitors and targeted degraders, have expanded the repertoire of medicinal chemists. Molecules with such modes of action have a large potential not only as drugs but also as chemical probes. Criteria have previously been established to describe the potency, selectivity, and properties of small-molecule probes that are qualified to enable the interrogation and validation of drug targets. These definitions have been tailored to reversibly acting modulators but fall short in their applicability to other modalities. While initial guidelines have been proposed, we delineate here a full set of criteria for the characterization of covalent, irreversible inhibitors as well as heterobifunctional degraders ("proteolysis-targeting chimeras", or PROTACs) and molecular glue degraders. We propose modified potency and selectivity criteria compared to those for reversible inhibitors. We discuss their relevance and highlight examples of suitable probe and pathfinder compounds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ubiquitin-Protein LigasesProteolysis

Substanzen

Ubiquitin-Protein Ligases

Autor:innen und Institutionen

  • Medicinal Chemistry, Global Research & Development, Merck Healthcare KGaA, 64293 Darmstadt, Germany.
  • Discovery Chemistry, Genentech, South San Francisco, California 94080, United States.
  • Molecular Innovation, Indiana Biosciences Research Institute, Indianapolis, Indiana 64202, United States.
  • Department of Cell and Chemical Biology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
  • Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, Sutton SM2 5NG, United Kingdom.
  • Chemical Probes Portal, https://www.chemicalprobes.org/.

ORCID-Profile: Ingo V Hartung, Joachim Rudolph, Mary M Mader, Monique P C Mulder, Paul Workman

Förderung

  • Wellcome Trust
  • Cancer Research UK

Zitieren

APA

Hartung, I. V., Rudolph, J., Mader, M. M., Mulder, M. P. C., & Workman, P. (2023). Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes. Journal of Medicinal Chemistry, 66(14), 9297-9312. https://doi.org/10.1021/acs.jmedchem.3c00550

Vancouver

Hartung IV, Rudolph J, Mader MM, Mulder MPC, Workman P. Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes. Journal of Medicinal Chemistry. 2023;66(14):9297-9312. doi:10.1021/acs.jmedchem.3c00550

BibTeX
@article{Hartung2023,
  author = {Hartung, Ingo V and Rudolph, Joachim and Mader, Mary M and Mulder, Monique P C and Workman, Paul},
  title = {Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  volume = {66},
  number = {14},
  pages = {9297--9312},
  doi = {10.1021/acs.jmedchem.3c00550}
}
Kostenlos starten →